MARKET

AMPE

AMPE

Ampio Pharma
AMEX
0.8550
+0.0350
+4.27%
Opening 11:25 03/28 EDT
OPEN
0.8200
PREV CLOSE
0.8200
HIGH
0.8800
LOW
0.8200
VOLUME
12.15K
TURNOVER
0
52 WEEK HIGH
8.30
52 WEEK LOW
0.7000
MARKET CAP
970.73K
P/E (TTM)
-0.0740
1D
5D
1M
3M
1Y
5Y
Ampio Pharmaceuticals Q4 EPS $(2.48) Up From $(3.60) YoY
Benzinga · 11h ago
AMPE Stock Earnings: Ampio Pharmaceuticals Reported Results for Q4 2023
Ampio Pharmaceuticals reported earnings per share of -$2.48 for the first quarter. The company did not report any revenue for the quarter. Ampo Pharmaceuticals is not listed as a company in the S&P 500 index of large companies on Tuesday.
Investorplace · 12h ago
GOEV, NBSE and FLGC among pre-market losers
GOEV, NBSE and FLGC among pre-market losers. NeuBase Therapeutics (NBSE) -58%. AppTech Payments Corp (APCX) announces proposed underwritten public offering. Bluebird bio (BLUE) reports Q4 results.
Seeking Alpha · 2d ago
Ampio Shares Fall 22% as Co. Plans to Voluntarily Delist From NYSE American
Ampio Pharmaceuticals plans to voluntarily delist shares from the NYSE American Exchange. The company's stock hit a 52-week low of $1.50 on March 7. Ampio says it plans to suspend its reporting obligations under the Securities and Exchange Act of 1934. The delisting is expected to become effective April 14.
Dow Jones · 2d ago
Ampio Reports Voluntary Delisting And SEC Deregistration
Benzinga · 2d ago
Ampio Pharmaceuticals announces voluntary delisting and SEC deregistration
Ampio Pharmaceuticals announces voluntary delisting and SEC deregistration. Shares of AMPE sunk 38.7% in extended trading. The company expects the delisting to become effective on April 14, 2024. AMPE's board determined to voluntarily delist its common stock from the NYSE American and deregister its stock.
Seeking Alpha · 2d ago
Ampio Announces Voluntary Delisting and SEC Deregistration
Ampio Pharmaceuticals, Inc. Will voluntarily delist its common stock from the NYSE American and deregister its stock in April 2024. The Company has previously focused on the development of a potential treatment for osteoarthritis. The pain reduction benefit was not observed in the company's OA-201 program. The company intends to suspend its reporting obligations under the Exchange Act.
PR Newswire · 2d ago
Weekly Report: what happened at AMPE last week (0318-0322)?
Weekly Report · 3d ago
More
About AMPE
Ampio Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the preclinical development of AR-300, and is conducting studies to evaluate the efficacy of AR-300 in osteoarthritis-related pain. The Company is primarily targeting the clinical development of AR-300 for the treatment of osteoarthritis of the knee (OAK). AR-300 is a small-molecule formulation that has demonstrated anti-inflammatory properties in vitro and protection of cartilage in preclinical rat meniscal tear studies.

Webull offers Ampio Pharmaceuticals Inc stock information, including AMEX: AMPE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMPE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AMPE stock methods without spending real money on the virtual paper trading platform.